Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...

Despite the regulatory setback, analysts appear optimistic, noting that Harmony’s long-term prospects remain bright given the ...

By some estimates, nearly half of the world's population suffers from a sleep disorder of some kind. Whether it be sleep ...

Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a ...

Harmony Biosciences is facing more of a nightmare than sweet dreams on the road to securing a new use for its excessive ...

Harmony Biosciences Holdings said the Food and Drug Administration has turned away its application seeking expanded approval of its Wakix narcolepsy drug for the treatment of excessive daytime ...

Harmony Biosciences' ( NASDAQ: HRMY) stock fell about 7.3% after U.S. FDA notified the company that it will not review the ...

An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Hypersomnia is a common but overlooked sleep issue in bipolar disorder. Learn how excessive sleep affects mood stability, ...